October 25, 2011
Pharmacosmos A/S, Denmark, announced today the launch of
the company's product Monofer® in Germany. The Danish company has
entered into collaboration with Medice Pharma GmbH & Co. in
Iserlohn, Germany.
The German company is responsible for the marketing of Monofer®
in Germany and joins Pharmacosmos' line of trusted
partners.
Lars Christensen, MD, President and CEO of Pharmacosmos, said: "We
are delighted to team up with Medice as our partner for Monofer® in
Germany and we look forward to the collaboration. Medice is a
highly professional company specialized in the treatment of
anaemia."
Richard Ammer, MD, PhD, General Manager of Medice, said: "Patients
suffering from iron deficiency anaemia will benefit from fast high
dose therapy, which will result in fewer hospital visits for
patients. Monofer® offers high dose opportunities in a single
administration and we believe Monofer® will become a very important
product in the treatment of iron deficiency anaemia in
Germany."
Monofer® (iron isomaltoside 1000) is an intravenous iron compound
based on an innovative chemical structure. Monofer® is indicated
for treatment of iron deficiency anaemia and offers high dose
administration up to 20mg/kg in 15-60 minutes. Monofer® offers most
patients a full iron correction in just one visit and no test dose
is required. Iron deficiency anaemia is a global health problem and
Monofer® has the potential to cure millions of patients
world-wide.
Monofer® is registered in several countries and is currently
available in UK, Ireland, Denmark, Sweden, Norway, Finland,
Netherlands, Germany and Poland.
Further information
Lars Christensen, MDPresident and CEO
T: +45 59 48 59 59
Richard Ammer, MD, PhDGeneral Manager
T: +49 2371 937-0
About Medice Pharma GmbH & Co.
Medice is based in Iserlohn, Germany, and is a
fully-integrated, mid-sized family-owned pharmaceutical enterprise.
The company develops, manufactures and distributes high-quality
drugs, pharmaceutical products and medical devices throughout
Germany, Europe and key international markets and holds leading
positions in defined niche indications. Likewise, Medice has a
broad portfolio for patients with renal insufficiency and is the
first supplier with Epoetin and iron to treat anemia.
www.medice.eu.
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals, patients suffering
from iron deficiency and veterinary treatments. .
Pharmacosmos is a family-owned
Danish company and operates in more than 50 countries across
Europe, the Americas and Asia. Its facilities are approved by both
the Danish Medicines Agency and the US Food & Drug
Administration.